492 related articles for article (PubMed ID: 33937624)
21. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
Nielsen KV; Ejlertsen B; Müller S; Møller S; Rasmussen BB; Balslev E; Lænkholm AV; Christiansen P; Mouridsen HT
Breast Cancer Res Treat; 2011 Jun; 127(2):345-55. PubMed ID: 20556506
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
23. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
24. Activating
Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
[TBL] [Abstract][Full Text] [Related]
25. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
Herzog SK; Fuqua SAW
Br J Cancer; 2022 Feb; 126(2):174-186. PubMed ID: 34621045
[TBL] [Abstract][Full Text] [Related]
26. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
27. Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.
Reinert T; Gonçalves R; Bines J
Curr Treat Options Oncol; 2018 Apr; 19(5):24. PubMed ID: 29666928
[TBL] [Abstract][Full Text] [Related]
28. ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.
Karsono R; Haryono SJ; Karsono B; Harahap WA; Pratiwi Y; Aryandono T
BMC Cancer; 2021 Dec; 21(1):1348. PubMed ID: 34930150
[TBL] [Abstract][Full Text] [Related]
29. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM; Jeselsohn RM
Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
[TBL] [Abstract][Full Text] [Related]
30. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
31. Estrogen receptor mutations and their role in breast cancer progression.
Alluri PG; Speers C; Chinnaiyan AM
Breast Cancer Res; 2014 Dec; 16(6):494. PubMed ID: 25928204
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
33. Fulvestrant in management of hormone receptor-positive metastatic breast cancer.
Shafaee MN; Ellis MJ
Future Oncol; 2018 Aug; 14(18):1789-1800. PubMed ID: 29783894
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
[TBL] [Abstract][Full Text] [Related]
35. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
[TBL] [Abstract][Full Text] [Related]
36. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
[TBL] [Abstract][Full Text] [Related]
37. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.
Li L; Lin L; Veeraraghavan J; Hu Y; Wang X; Lee S; Tan Y; Schiff R; Wang XS
Breast Cancer Res; 2020 Aug; 22(1):84. PubMed ID: 32771039
[TBL] [Abstract][Full Text] [Related]
39. Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
Allouchery V; Beaussire L; Perdrix A; Sefrioui D; Augusto L; Guillemet C; Sarafan-Vasseur N; Di Fiore F; Clatot F
Breast Cancer Res; 2018 May; 20(1):40. PubMed ID: 29769099
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
Gou X; Anurag M; Lei JT; Kim BJ; Singh P; Seker S; Fandino D; Han A; Rehman S; Hu J; Korchina V; Doddapaneni H; Dobrolecki LE; Mitsiades N; Lewis MT; Welm AL; Li S; Lee AV; Robinson DR; Foulds CE; Ellis MJ
Cancer Res; 2021 Dec; 81(24):6259-6272. PubMed ID: 34711608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]